Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week

Eli Lilly’s shares are down on Wednesday after hitting an all-time high the prior week, reflecting a near-term pullback despite separately reporting positive real-world data for its weight-loss drug Zepbound. The update appears more supportive than decisive for the stock’s immediate trading direction, suggesting the move is driven largely by positioning after recent gains rather than deteriorating fundamentals.